BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chugai Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Chugai Pharma's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Multiple Therapies in Biomarker-selected Participants With Resect
 able Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03148418-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03148418)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Participants Previou
 sly Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Ate
 zolizumab Study (IMbrella A)\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03148418
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07074977-1524@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07074977)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Proof of Concept Stud
 y to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults
  With Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 emolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07074977
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05871970-10925@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TARA-002: Phase 2 readout est. (NCT05871970)
DESCRIPTION:TARA-002\, phase 2.\nStudy: Safety and Efficacy Study of Intrac
 ystic TARA-002 for the Treatment of Lymphatic Malformations in Participant
 s 6 Months to Less Than 18 Years of Age\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 1970
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077723-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04077
 723)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 to Evaluate the Safety\, Pharmacokinetics and Preliminary Anti-Tumor Activ
 ity of Englumafusp Alfa in Combination With Obinutuzumab and in Combinatio
 n With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Partic
 ipants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma\nEstimated p
 rimary completion: 28 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04077723
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2016@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT05170204)
DESCRIPTION:Alecensa (Alectinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Therapies in 
 Cohorts of Participants With Locally Advanced\, Unresectable\, Stage III N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517020
 4
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672549-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672549)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Platform
  Trial for Pediatric Participants With Obesity or Overweight (LY900040)\nE
 stimated primary completion: February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/orforglipron#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06672549
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535244-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT05535
 244)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturatio
 n Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 26 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05535244
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04873362-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04873362)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study Evaluating the Efficacy
  and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine 
 for Participants With HER2-Positive Breast Cancer at High Risk of Recurren
 ce Following Preoperative Therapy\nEstimated primary completion: 31 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048733
 62
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613307-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07613307)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who
  Observe Ramadan Fasting\nEstimated primary completion: May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07613307
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02650401-2220@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 1/2 readout est. (NCT02650401)
DESCRIPTION:Entrectinib\, phase 1/2.\nStudy: Study Of Entrectinib (Rxdx-101
 ) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or
  Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02650401
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00781612-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT00781612)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Safety Extension Study of Tra
 stuzumab Emtansine in Participants Previously Treated With Trastuzumab Emt
 ansine Alone or in Combination With Other Anti-Cancer Therapy in One of th
 e Parent Studies\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT00781612
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Atezolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies
  as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112965-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05112965)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: An Extension Study in Participa
 nts Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Spo
 nsored Atezolizumab Study (IMbrella C)\nEstimated primary completion: 30 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 112965
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524871-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04524871)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Pa
 tients With Advanced Liver Cancers (Morpheus-Liver)\nEstimated primary com
 pletion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04524871
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096779-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06096779)
DESCRIPTION:Atezolizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A St
 udy Evaluating Atezolizumab\, With or Without Bevacizumab\, in Participant
 s With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
 hosis\nEstimated primary completion: 30 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06096779
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04594798-4915@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04594798)
DESCRIPTION:Rituxan (Rituximab)\, phase 2.\nStudy: A Study of Polatuzumab V
 edotin\, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL\nE
 stimated primary completion: 31 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04594798
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972459-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972459)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and a
 t Least One Weight-Related Comorbidity\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 72459
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972472)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and T
 ype 2 Diabetes\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06972472
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06993792)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Obesity or Overw
 eight With and Without Type 2 Diabetes\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 93792
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747506-11026@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07747506)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: Continued Access to Avutometinib in Combination Wi
 th Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (
 LGSOC)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-c
 o-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07747506
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084936-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0608493
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Study to
  Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Partic
 ipants With Relapsed/Refractory Mantle Cell Lymphoma\nEstimated primary co
 mpletion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06084936
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948422)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Hypertension and
  Obesity or Overweight: (ATTAIN-Hypertension Screening)\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06948422
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948435)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL1\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948435
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06952530)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL2\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06952530
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05207670-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0520767
 0)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: A Study Ev
 aluating the Safety\, Efficacy\, and Pharmacokinetics of Mosunetuzumab Mon
 otherapy in Participants With Select B-Cell Malignancies\nEstimated primar
 y completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05207670
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047080-4915@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06047080)
DESCRIPTION:Rituxan (Rituximab)\, phase 3.\nStudy: An Open-Label Study Comp
 aring Glofitamab and Polatuzumab Vedotin + Rituximab\, Cyclophosphamide\, 
 Doxorubicin\, and Prednisone Versus Pola-R-CHP in Previously Untreated Pat
 ients With Large B-Cell Lymphoma\nEstimated primary completion: 1 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047080
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:enicepatide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:enicepatide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study o
 f Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Over
 weight\nEstimated primary completion: 12 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672939-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06672939)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Adolescent Participants With Obesity\, or Ove
 rweight With Related Comorbidities\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06672
 939
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Study Evaluating the Efficacy
  and Safety of Biomarker-Driven Therapies in Patients With Persistent or R
 ecurrent Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04931342
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790861-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07790861)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweig
 ht and Weight-Related Health Problems\nEstimated primary completion: March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07790
 861
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202884-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07202884)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Female Participants With Stress Urinary Incontinence Who 
 Have Obesity or Overweight\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07202884
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408638-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0440863
 8)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3.\nStudy: A Phase II
 I Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplati
 n vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participan
 ts With Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated prima
 ry completion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tocilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04408638
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153471-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07153471)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and O
 steoarthritis (OA) of the Knee\nEstimated primary completion: April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07153471
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480356-10925@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TARA-002: Phase 3 readout est. (NCT07480356)
DESCRIPTION:TARA-002\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Efficacy and Safety of Intravesical TARA-002 Compared With Investigator'
 s Choice of Intravesical Chemotherapy in Participants With BCG-naïve High
 -grade Non-muscle Invasive Bladder Cancer\nEstimated primary completion: A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07480
 356
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047690-1524@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07047690)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: A Study of Nemolizuma
 b for the Treatment of Adults With Systemic Sclerosis\nEstimated primary c
 ompletion: 28 May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07047690
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223593-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07223593)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Efficacy and Safety of Orforglipron in Participants W
 ith Peripheral Artery Disease\nEstimated primary completion: June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07223593
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Study in Patients Previously 
 Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezoliz
 umab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660835-1524@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07660835)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2\, Atopic Dermatitis.\nStudy: P
 harmacokinetics\, Safety and Efficacy of Nemolizumab in Participants Aged 
 6 to 23 Months With Moderate-to Severe Atopic Dermatitis\nEstimated primar
 y completion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07660835
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351045-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351045)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight Without Type 2 Diabetes\nEstimated primary completion: 24 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 51045
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT05583
 617)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Safety and Efficacy of Multiple Treatments in Participants 
 With Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351058-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351058)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight and Type 2 Diabetes\nEstimated primary completion: 7 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073510
 58
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072781-11026@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 3 readout
  est. (NCT06072781)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 3\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib (VS-6766) + Defactinib (VS
 -6063) in Recurrent Low-Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 15 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06072781
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-11026@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT07020221)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated S
 olid Tumors\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzy
 nja-co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07020221
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04712643-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT04712643)
DESCRIPTION:Atezolizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: A St
 udy of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in P
 atients With Untreated Heaptocellular Carcionma\nEstimated primary complet
 ion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04712643
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03075696-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT03075
 696)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Dose E
 scalation Study of Glofitamab (RO7082859) as a Single Agent and in Combina
 tion With Obinutuzumab\, Administered After a Fixed\, Single Pre-treatment
  Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-
 hodgkin's Lymphoma\nEstimated primary completion: 30 March 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03075696
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889648-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:enicepatide: Phase 3 readout est. (NCT07889648)
DESCRIPTION:enicepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Clinical Stu
 dy to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participan
 ts With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose
 -Lowering Medications\nEstimated primary completion: 2 April 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07889648
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0782506
 4)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2.\nStudy: Cevostamab
  in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting 
 CAR T-Cell Therapy in Participants With Previously Treated Multiple Myelom
 a\nEstimated primary completion: 13 April 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Treatment Combinations in Participants With Brea
 st Cancer\nEstimated primary completion: 30 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04802759
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794579-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07794579)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Participants With Overweight at Risk of Development of Ob
 esity-Related Complications or Progression to Class 1 Obesity\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orforglipron#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07794579
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533775-4915@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05533775)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2.\nStudy: A Study to Evaluate Gl
 ofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and 
 Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgki
 n Lymphoma\nEstimated primary completion: 30 November 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05533775
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668336-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07668336)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric P
 articipants With Type 2 Diabetes\nEstimated primary completion: March 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07668336
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04246086-6083@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300906
DTEND;VALUE=DATE:20300907
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 1/2 readout est. (NCT04246
 086)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 1/2.\nStudy: A Study 
 Evaluating the Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab +
  Lenalidomide (+Len)\, and the Safety\, Tolerability\, and Pharmacokinetic
 s of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymp
 homa\nEstimated primary completion: 6 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04246086
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Atezolizumab\, phase 1/2.\nStudy: A Study Evaluating the Effica
 cy and Safety of Multiple Treatment Combinations in Patients With Metastat
 ic or Locally Advanced Breast Cancer\nEstimated primary completion: 30 Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezoliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03424005
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05968326-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05968326)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: A Study of the Efficacy and Saf
 ety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versu
 s mFOLFIRINOX Alone in Participants With Resected PDAC\nEstimated primary 
 completion: 1 January 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05968326
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918846-159@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20310320
DTEND;VALUE=DATE:20310321
SUMMARY:enicepatide: Phase 3 readout est. (NCT07918846)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study Testi
 ng Enicepatide in Participants Living With Overweight or Obesity and Cardi
 ovascular Disease\nEstimated primary completion: 20 March 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07918846
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241390-117@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07241390)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: A Study of Orforglipron (LY3502970) on Cardiovascular
  Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chr
 onic Kidney Disease (ATTAIN-Outcomes)\nEstimated primary completion: Augus
 t 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 1390
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951179-10925@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:TARA-002: Phase 2 readout est. (NCT05951179)
DESCRIPTION:TARA-002\, phase 2\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Ad
 ults With High-grade Non-muscle Invasive Bladder Cancer\nEstimated primary
  completion: October 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tara-002#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05951179
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774718-2016@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20320228
DTEND;VALUE=DATE:20320229
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT04774718)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2.\nStudy: A Study Evaluating th
 e Safety\, Pharmacokinetics\, and Efficacy of Alectinib in Pediatric Parti
 cipants With ALK Fusion-Positive Solid or CNS Tumors\nEstimated primary co
 mpletion: 28 February 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04774718
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Atezolizumab\, phase 2.\nStudy: Tumor-agnostic Precision Immuno
 -oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
 \nEstimated primary completion: 25 September 2032. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-1962@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Atezolizumab\, phase 3.\nStudy: A Rollover Study for Participan
 ts Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored
  Study\nEstimated primary completion: 1 March 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
